{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:21:21Z","timestamp":1781277681125,"version":"3.54.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hawthorn\u2019s efficacy when added to contemporary evidence-based heart failure therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory patients aged \u226518 years with New York Heart Association (NYHA) class II-III chronic heart failure. All patients received conventional medical therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life (QOL) measures, peak oxygen consumption, and anaerobic threshold during maximal treadmill exercise testing, NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress and inflammation. There were no significant differences between groups in the change in 6 min walk distance (P = 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or inflammation. A modest difference in LVEF favoured hawthorn (P = 0.04). There were significantly more adverse events reported in the hawthorn group (P = 0.02), although most were non-cardiac.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure.<\/jats:p>\n                    <jats:p>This trial is registered in ClinicalTrials.gov ID: NCT00343902.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfp116","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T22:02:27Z","timestamp":1254261747000},"page":"990-999","source":"Crossref","is-referenced-by-count":51,"title":["Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial"],"prefix":"10.1093","volume":"11","author":[{"given":"Suzanna M.","family":"Zick","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Michigan , 1018 Fuller St., Ann Arbor, MI, 48109\u20130708 ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie Motyka","family":"Vautaw","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan , Ann Arbor, MI ,","place":["USA"]},{"name":"Ford Motor Credit Company , Dearborn, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan , Ann Arbor, MI ,","place":["USA"]},{"name":"The Center for Statistical Consulting and Research, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Aaronson","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,9,29]]},"reference":[{"key":"2026020203373419200_ejhfhfp116-bib-0001","first-page":"27","article-title":"Therapeutic effectiveness of Crataegus","volume":"114","author":"Weihmayr","year":"1996","journal-title":"Fortschr Med"},{"key":"2026020203373419200_ejhfhfp116-bib-0002","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/1099-1573(200009)14:6<428::AID-PTR618>3.0.CO;2-L","article-title":"Effects of extracts from flowering tops of Crataegus meyeri A. Pojark. on ischaemic arrhythmias in anaesthetized rats","volume":"14","author":"Garjani","year":"2000","journal-title":"Phytother Res"},{"key":"2026020203373419200_ejhfhfp116-bib-0003","first-page":"821","article-title":"In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms","volume":"47","author":"Chatterjee","year":"1997","journal-title":"Arzneimittel-Forschung"},{"key":"2026020203373419200_ejhfhfp116-bib-0004","first-page":"37","article-title":"Comparative study of the cardiovascular activity of shoots, leaves and flowers of Crataegus oxyacantha: 1. Electrical activity and arterial pressure in the rat","volume":"20","author":"Occhiuto","year":"1986","journal-title":"Plantes medicinales et phytotherapie"},{"key":"2026020203373419200_ejhfhfp116-bib-0005","first-page":"52","article-title":"Comparative study of the cardiovascular activity of shoots, leaves and flowers of Crataegus oxyacantha: 2. Action of extracts and isolated pure active principles on the isolated rabbit heart","volume":"20","author":"Occhiuto","year":"1986","journal-title":"Plantes medicinales et phytotherapie"},{"key":"2026020203373419200_ejhfhfp116-bib-0006","first-page":"28","article-title":"WS 1442 (Crataegus-Special Extract) increases contractile force in the myocardium of humans with congestive heart failure","volume":"30","author":"Brixius","year":"1998","journal-title":"Herz-Kreislauf"},{"key":"2026020203373419200_ejhfhfp116-bib-0007","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0006-2952(79)90249-1","article-title":"Flavonoids are selective cyclic GMP phosphodiesterase inhibitors","volume":"28","author":"Ruchstuhl","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"2026020203373419200_ejhfhfp116-bib-0008","first-page":"842","article-title":"Myocardial effects of flavonoids from Crataegus species","volume":"45","author":"Schussler","year":"1995","journal-title":"Arzneimittelforschung"},{"key":"2026020203373419200_ejhfhfp116-bib-0009","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1099-1573(200012)14:8<612::AID-PTR677>3.0.CO;2-T","article-title":"Antioxidants in medicinal plant extracts. A research study of the antioxidant capacity of Crataegus, Hamamelis and Hydrastis.","volume":"14","author":"Periera da Silva","year":"2000","journal-title":"Phytother Res"},{"key":"2026020203373419200_ejhfhfp116-bib-0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/food.200390045","article-title":"Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts","volume":"47","author":"Bahorun","year":"2003","journal-title":"Nahrung"},{"key":"2026020203373419200_ejhfhfp116-bib-0011","volume-title":"Natural Products as Medicinal Agents: Plenary Lectures of the International Research Congress on Medicinal Plant Research, Stuttgart","author":"Masquelier","year":"1981"},{"key":"2026020203373419200_ejhfhfp116-bib-0012","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0002-9343(03)00131-1","article-title":"Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials","volume":"114","author":"Pittler","year":"2003","journal-title":"Am J Med"},{"key":"2026020203373419200_ejhfhfp116-bib-0013","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejheart.2008.04.008","article-title":"The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure","volume":"10","author":"Zick","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203373419200_ejhfhfp116-bib-0014","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1161\/01.CIR.95.12.2660","article-title":"Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation","volume":"95","author":"Aaronson","year":"1997","journal-title":"Circulation"},{"key":"2026020203373419200_ejhfhfp116-bib-0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQoL-A new facility for the measurement of health related quality of life","volume":"16","author":"Group TE","year":"1990","journal-title":"Health Policy"},{"key":"2026020203373419200_ejhfhfp116-bib-0016","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"2026020203373419200_ejhfhfp116-bib-0017","first-page":"352","article-title":"Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study","volume":"111","author":"Leuchtgens","year":"1993","journal-title":"Fortschr Med"},{"key":"2026020203373419200_ejhfhfp116-bib-0018","first-page":"805","article-title":"Treatment of decreasing cardiac performance. Therapy using standardized Crataegus extract in advanced age","volume":"104","author":"O\u2019Connolly","year":"1986","journal-title":"Fortschritte der Medizin"},{"key":"2026020203373419200_ejhfhfp116-bib-0019","first-page":"4331","article-title":"The treatment of mild stable forms of angina pectoris using Crategutt novo","volume":"33","author":"Hanack","year":"1983","journal-title":"Therapiewoche"},{"key":"2026020203373419200_ejhfhfp116-bib-0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1078\/0944-7113-00041","article-title":"Clinical efficacy of Crataegus Extract WS 1442 in congestive heart failure NYHA Class II","volume":"8","author":"Zapfe","year":"2001","journal-title":"Phytomedicine"},{"key":"2026020203373419200_ejhfhfp116-bib-0021","first-page":"S7","article-title":"Effectiveness of hawthorn extract at a dosage of 3 \u00d7 100 mg per day. Multicentre double-blind trial with 85 NYHA stage II heart failure patients","volume":"136","author":"Bodigheimer","year":"1994","journal-title":"Munch Med Wschr"},{"key":"2026020203373419200_ejhfhfp116-bib-0022","first-page":"291","article-title":"Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)","volume":"114","author":"Weikl","year":"1996","journal-title":"Fortschr Med"},{"key":"2026020203373419200_ejhfhfp116-bib-0023","first-page":"805","article-title":"Treatment of heart failure","volume":"104","author":"O\u2019Connolly","year":"1986","journal-title":"Fortschr Med"},{"key":"2026020203373419200_ejhfhfp116-bib-0024","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1067\/mhj.2002.121463","article-title":"Efficacy and safety of Crataegus Extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association Class-III heart failure","volume":"143","author":"Tauchert","year":"2002","journal-title":"Am Heart J"},{"key":"2026020203373419200_ejhfhfp116-bib-0025","first-page":"S27","article-title":"Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Multicentre double-blind study with 132 NYHA stage II heart failure patients","volume":"136","author":"Tauchert","year":"1994","journal-title":"Munchener Medizinische Wochenschrift"},{"key":"2026020203373419200_ejhfhfp116-bib-0026","doi-asserted-by":"crossref","DOI":"10.1097\/00000542-198909001-00049","article-title":"The mean blood pressure\u2014heart rate quotient and systolic blood pressure\u2014heart rate product are not useful indicators of myocardial ischemia","volume":"71","author":"Strauss","year":"1989","journal-title":"Anesthesiology"},{"key":"2026020203373419200_ejhfhfp116-bib-0027","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.1993.03510140062030","article-title":"Prediction of mortality and morbidity with a 6 min walk test in patients with left ventricular dysfunction","volume":"270","author":"Bittner","year":"1993","journal-title":"JAMA"},{"key":"2026020203373419200_ejhfhfp116-bib-0028","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1067\/mhj.2001.118468","article-title":"RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure","volume":"142","author":"Demers","year":"2001","journal-title":"Am Heart J"},{"key":"2026020203373419200_ejhfhfp116-bib-0029","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.CIR.83.3.778","article-title":"Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure","volume":"83","author":"Mancini","year":"1991","journal-title":"Circulation"},{"key":"2026020203373419200_ejhfhfp116-bib-0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ejheart.2008.10.004","article-title":"Crataegus extract WS\u00ae 1442, congestive heart failure, survival, efficacy, safety, controlled randomized trial","volume":"10","author":"Holubarsch","year":"2008","journal-title":"Eur J Heart Failure"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfp116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfp116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfp116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfp116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/10\/990\/66546405\/eurjhf_11_10_990.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/10\/990\/66546405\/eurjhf_11_10_990.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:37:45Z","timestamp":1770021465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/11\/10\/990\/8438925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,29]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,9,29]]},"published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfp116","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,10]]},"published":{"date-parts":[[2009,9,29]]}}}